Company / Operating Cash Flow
Trevi Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$38.3M
FY2024
5-year range
-$38.3M / -$28.2M
FY2020-FY2024
Trend
-20.6%
vs FY2023
Sector context
#90 of 216
Health Care
What the data says
At -$38M, Trevi Therapeutics, Inc.'s operating cash flow ranks #90 of 216 in the Health Care sector. Declined from -$28M to -$38M over the past 2 years.
Based on SEC 10-K filings.
-$38M in FY2024.
Declined from -$28M to -$38M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#90 of 216 in Health CareTop 42% of 216This company -$38.3M Sector average $658.7M
▼
-105.8% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 20.6% year-over-year.
- Ranks #90 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$38.3M | -20.6% |
| FY2023 | -$31.7M | -12.5% |
| FY2022 | -$28.2M | +2.7% |
| FY2021 | -$28.9M | +0.2% |
| FY2020 | -$29.0M | -25.6% |
| FY2019 | -$23.1M | -26.3% |
| FY2018 | -$18.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026